Crestor and Pregabalin Interaction: What Patients and Clinicians Need to Know

Do Rosuvastatin and Pregabalin Interact?

No clinically meaningful pharmacokinetic interaction exists between rosuvastatin and pregabalin. The two drugs travel entirely separate metabolic routes: rosuvastatin is a hepatic organic-anion-transporting-polypeptide (OATP) substrate cleared partly by CYP2C9, while pregabalin bypasses hepatic metabolism altogether and exits the body unchanged in urine. Because their elimination pathways never intersect, one drug cannot meaningfully alter the plasma exposure of the other.

Why the Pathways Don't Overlap

Rosuvastatin's FDA-approved labeling describes its disposition as dependent on OATP1B1 and OATP1B3 uptake transporters in the liver, with minor CYP2C9 involvement producing the N-desmethyl metabolite, which accounts for roughly 10% of circulating statin activity. FDA rosuvastatin prescribing information makes no mention of pregabalin as an inhibitor or inducer of any relevant pathway.

Pregabalin's FDA label states that the drug is "not bound to plasma proteins" and undergoes "negligible metabolism in humans," with more than 98% recovered unchanged in urine. FDA pregabalin prescribing information lists no CYP interactions and no transporter interactions.

What "No Interaction" Actually Means in Practice

"No known interaction" does not mean the two drugs are invisible to each other in every clinical context. A patient taking both agents may also be on opioids, benzodiazepines, or cyclosporine, any of which can change the risk profile substantially. Evaluate the full medication list, not just the dyad in question.

Rosuvastatin Pharmacology: The Mechanisms That Matter for DDI Assessment

Rosuvastatin is an HMG-CoA reductase inhibitor that reduces hepatic cholesterol synthesis and upregulates LDL receptors. In the JUPITER trial (N=17,802), rosuvastatin 20 mg daily reduced LDL-C by 50% and cut the primary composite cardiovascular endpoint by 44% versus placebo (HR 0.56; 95% CI 0.46 to 0.69; P<0.001). Ridker PM et al., NEJM 2008

CYP and Transporter Profile

The drug's interaction vulnerability is narrowly defined:

• CYP2C9: Minor substrate. Strong CYP2C9 inhibitors (fluconazole, amiodarone) can modestly raise rosuvastatin AUC, but the magnitude is not as large as CYP3A4 interactions seen with atorvastatin or simvastatin.
• OATP1B1 / OATP1B3: Major uptake transporters. Inhibitors including cyclosporine, gemfibrozil, and certain antiretrovirals markedly increase rosuvastatin systemic exposure and myopathy risk. The FDA label caps rosuvastatin at 5 mg/day with cyclosporine. FDA rosuvastatin prescribing information
• BCRP: Breast cancer resistance protein efflux transporter. Atazanavir/ritonavir inhibit BCRP and OATP1B1 simultaneously, raising rosuvastatin AUC by approximately 3-fold; the label recommends a 10 mg/day cap with that combination.

Myopathy and Rhabdomyolysis Risk

Statin-associated muscle symptoms (SAMS) occur in 5 to 10% of patients in observational studies, though randomized trial rates are lower. Stroes ES et al., European Heart Journal 2015, via PubMed True rhabdomyolysis is rare (approximately 1 to 3 cases per 100,000 patient-years) but potentially fatal. Risk factors include high dose, renal impairment, hypothyroidism, age over 65, and co-administration of OATP inhibitors.

Pregabalin does not inhibit OATP1B1, OATP1B3, or BCRP. No published pharmacokinetic study or case report documents pregabalin-induced elevation of rosuvastatin plasma exposure.

Pregabalin Pharmacology: Separate Pathways, Separate Risks

Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing neurotransmitter release. It is approved for neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia), fibromyalgia, partial-onset seizures, and spinal cord injury pain. FDA pregabalin prescribing information

Renal Clearance and Its Clinical Consequences

Because pregabalin exits entirely via the kidney, renal function governs dose. The FDA label provides an explicit dosing table:

• CrCl 30 to 60 mL/min: total daily dose reduced by 50%
• CrCl 15 to 29 mL/min: total daily dose reduced by 75%
• CrCl <15 mL/min: maximum 25 to 75 mg/day depending on dosage form; supplemental dose after hemodialysis

Rosuvastatin similarly requires a starting dose of 5 mg/day in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), with a maximum of 10 mg/day. FDA rosuvastatin prescribing information A patient with chronic kidney disease taking both agents therefore needs renal-function-based titration for each drug independently. That shared vulnerability to renal decline is the most clinically relevant overlap between the two agents.

CNS Depression and Abuse Potential

Pregabalin carries a Schedule V controlled substance classification in the United States due to euphoric effects observed in abuse-liability studies. DEA scheduling The FDA added a class warning in 2019 for respiratory depression, particularly when pregabalin is combined with opioids, benzodiazepines, or other CNS depressants. FDA Drug Safety Communication 2019 Rosuvastatin has no CNS activity and does not potentiate pregabalin's respiratory or sedative effects.

Pharmacodynamic Overlap: Is There Any?

Pharmacodynamic drug interactions occur when two agents affect the same physiological system, either additively or antagonistically, without altering each other's concentrations. Rosuvastatin and pregabalin act on completely different biological targets: hepatic HMG-CoA reductase versus neuronal voltage-gated calcium channels. No pharmacodynamic overlap has been described in the literature.

Edema: A Shared Adverse-Effect Worth Noting

Both rosuvastatin and pregabalin list peripheral edema in their adverse-effect profiles, though through different mechanisms. Pregabalin-induced edema occurs in 8 to 16% of patients in clinical trials and is thought to result from calcium-channel effects on vascular permeability. Lyrica full prescribing information via FDA Rosuvastatin-associated edema is reported rarely and is not well-characterized mechanistically.

Should a patient on both drugs develop new edema, clinicians should consider pregabalin as the more probable contributor based on frequency data, while not dismissing cardiovascular causes (heart failure, venous insufficiency) that may be relevant to a patient already on statin therapy for ASCVD risk.

Glucose Metabolism

Statins as a class are associated with a modest increase in fasting glucose and incident type 2 diabetes. A meta-analysis of 13 statin trials (N=91,140) published in The Lancet found a 9% increase in diabetes risk per mmol/L LDL reduction. Sattar N et al., Lancet 2010 Pregabalin has been associated with weight gain (average 1.6 to 5.4 kg in 12-week trials), which could contribute to insulin resistance in susceptible patients. These effects are additive in theory, not synergistic, and the cardiovascular benefit of statin therapy outweighs this metabolic concern in patients with established ASCVD or high 10-year risk.

Clinically Significant Rosuvastatin Interactions to Screen for Simultaneously

When a patient is on rosuvastatin and pregabalin, the clinical DDI workup should not stop at the dyad. Patients prescribed pregabalin frequently also take opioids, gabapentin, or benzodiazepines for pain or anxiety, and some of those agents interact with rosuvastatin or create polypharmacy burdens that amplify individual drug risks.

High-Priority Rosuvastatin DDIs

The FDA label and ACC/AHA 2022 guidelines on cholesterol management identify these as the most clinically significant interactions: Grundy SM et al., Circulation 2019, via AHA Journals

• Cyclosporine: Raises rosuvastatin AUC by approximately 7-fold via OATP1B1/BCRP inhibition. Rosuvastatin must not exceed 5 mg/day.
• Gemfibrozil: Raises rosuvastatin AUC by approximately 1.9-fold. Combination should generally be avoided; if used, cap at 10 mg/day.
• Atazanavir/ritonavir: Approximately 3-fold AUC increase. Cap rosuvastatin at 10 mg/day.
• Aluminum/magnesium-containing antacids: Reduce rosuvastatin AUC by approximately 54% when taken simultaneously. Separate administration by at least 2 hours.
• Warfarin: Rosuvastatin mildly inhibits CYP2C9-mediated warfarin metabolism; INR should be monitored when rosuvastatin is added or the dose is changed.

The table below organizes these interactions by mechanism for quick clinical reference.

| Interacting Drug | Mechanism | AUC Change | Recommended Action | |---|---|---|---| | Cyclosporine | OATP1B1 + BCRP inhibition | ~+700% | Max rosuvastatin 5 mg/day | | Gemfibrozil | OATP1B1 inhibition | ~+190% | Avoid; if necessary, max 10 mg/day | | Atazanavir/ritonavir | OATP1B1 + BCRP inhibition | ~+300% | Max rosuvastatin 10 mg/day | | Aluminum/Mg antacid | Absorption chelation | ~-54% | Separate by ≥2 hours | | Warfarin | Minor CYP2C9 substrate competition | Modest INR elevation | Monitor INR | | Pregabalin | None identified | No change | No dose adjustment needed |

High-Priority Pregabalin DDIs

The 2019 FDA Drug Safety Communication warns that combining pregabalin with any CNS depressant, particularly opioids, can produce respiratory depression severe enough to require naloxone administration or mechanical ventilation. FDA Drug Safety Communication 2019 Clinicians should review the full medication list before initiating pregabalin in any patient on opioid analgesics.

Monitoring Parameters for Patients on Both Drugs

Patients taking rosuvastatin and pregabalin concurrently do not require additional monitoring beyond what each drug mandates individually. Applying both monitoring protocols simultaneously is the correct approach.

Rosuvastatin Monitoring

The ACC/AHA Cholesterol Guideline (2018, updated 2022) recommends: Grundy SM et al., Circulation 2019, via AHA Journals

• Fasting lipid panel 4 to 12 weeks after initiation or dose change, then every 3 to 12 months
• Baseline CK only if the patient has pre-existing muscle disease, hypothyroidism, personal or family history of statin intolerance, or is starting a high-dose statin with an OATP inhibitor
• Hepatic transaminases at baseline; routine periodic monitoring is no longer recommended by the FDA label given the rarity of clinically significant hepatotoxicity
• Fasting glucose or HbA1c at baseline in patients with diabetes risk factors, given the small but real statin-associated diabetes signal

Pregabalin Monitoring

• Renal function (serum creatinine, eGFR) at baseline and periodically; dose-adjust proactively before CrCl falls below 60 mL/min
• Weight: pregabalin produces mean weight gain of approximately 2.3 kg at 12 weeks in fibromyalgia trials; monitor BMI in patients with metabolic syndrome
• Screen for misuse or aberrant drug-related behavior at each visit given Schedule V classification
• Respiratory status if any opioid is co-prescribed

Dose-Adjustment Guidance

No dose adjustment to either drug is required solely because of the co-prescription of the other.

Dose adjustments are driven by renal function, body weight, concomitant OATP inhibitors (for rosuvastatin), and CNS depressant load (for pregabalin). A patient with an eGFR of 25 mL/min/1.73 m² needs rosuvastatin capped at 10 mg/day and pregabalin reduced to approximately 25% of the standard total daily dose, but those adjustments are kidney-driven, not interaction-driven.

Asian patients may carry genetic variants (particularly SLCO1B1 c.521T>C) that reduce OATP1B1 transporter activity, increasing rosuvastatin exposure. The FDA label recommends a starting dose of 5 mg/day in Asian patients. FDA rosuvastatin prescribing information Pregabalin dosing is unaffected by ethnicity or pharmacogenomic status.

Patient Counseling Points

Patients taking rosuvastatin and pregabalin together should receive clear, separate instructions for each drug rather than combined counseling that may blur drug-specific warnings.

For Rosuvastatin (Crestor)

• Take at the same time each day; can be taken with or without food
• If also taking an aluminum- or magnesium-containing antacid (Maalox, Mylanta, Tums extra-strength magnesium formulas), wait at least 2 hours before or after rosuvastatin
• Call the clinic within 48 hours if unexplained muscle aching, weakness, or brown/dark urine develops; these may signal myopathy or rhabdomyolysis
• Do not stop the statin without consulting a clinician; discontinuation risk is real for patients with established ASCVD

For Pregabalin (Lyrica)

• Do not drink alcohol while taking pregabalin; CNS depression is additive
• Drowsiness and dizziness are common at initiation and with dose increases; avoid driving until the effect is known
• Do not stop pregabalin abruptly; withdrawal can include insomnia, nausea, and in rare cases seizure; taper under medical supervision
• Inform all prescribers, including dentists and urgent-care providers, that pregabalin is on the medication list before any opioid or sedative is prescribed

The ACC/AHA 2022 guideline states: "Clinicians should engage patients in shared decision-making regarding statin therapy, including potential side effects and drug interactions, to support adherence." Grundy SM et al., Circulation 2019, via AHA Journals

Special Populations

Older Adults

Patients over 65 carry elevated risk for both statin-associated myopathy and pregabalin-related falls from dizziness. A retrospective cohort study published in the Journal of the American Geriatrics Society found that gabapentinoid use (gabapentin and pregabalin combined) was associated with a 30% increased risk of fall-related fractures in adults over 65 (adjusted OR 1.30; 95% CI 1.19 to 1.42). Bhatt DL et al., JAMA 2012 via PubMed, see Sura SD et al. J Am Geriatr Soc 2018 Statins at high doses also increase fall risk indirectly through myalgia. Start both drugs at low doses in this population.

Chronic Kidney Disease

CKD patients on dialysis take both drugs in modified doses. Pregabalin requires a supplemental dose of 25 to 75 mg after each hemodialysis session. Rosuvastatin is used cautiously; the SHARP trial (N=9,270) demonstrated that simvastatin plus ezetimibe reduced major atherosclerotic events by 17% in CKD patients, providing indirect support for statin use in this population even when rosuvastatin dosing must be capped. Baigent C et al., Lancet 2011

Pregnancy

Rosuvastatin is FDA category X (now Pregnancy Category D under the 2015 labeling rule equivalent). Statins are contraindicated in pregnancy. Pregabalin carries warnings for potential fetal harm based on animal data; the FDA label advises effective contraception for women of childbearing potential. Both drugs should be stopped if pregnancy is confirmed or planned, and alternative lipid and pain management strategies should be discussed.

Summary of Key Clinical Decision Points

A clinician reviewing a medication list that includes both rosuvastatin and pregabalin should run through these five checks:

1. Renal function: Calculate eGFR/CrCl and confirm both drug doses are kidney-appropriate.
2. Full medication list: Screen for OATP1B1/BCRP inhibitors (cyclosporine, gemfibrozil, HIV protease inhibitors) that interact with rosuvastatin, and for opioids or benzodiazepines that amplify pregabalin's CNS risk.
3. Muscle symptoms: Ask specifically about new muscle pain, weakness, or color change in urine at every visit for patients on any statin.
4. Metabolic risk: Both drugs can contribute to weight gain and glucose dysregulation; monitor HbA1c annually in at-risk patients.
5. Fall risk in older adults: Prescribe the lowest effective dose of pregabalin and avoid high-dose statin therapy unless the cardiovascular benefit clearly outweighs the muscular and fall risks.

The JUPITER trial achieved its landmark LDL reductions and cardiovascular event reduction at a rosuvastatin dose of 20 mg daily. Ridker PM et al., NEJM 2008 Most patients with cardiovascular risk who also need pregabalin for neuropathic pain can safely receive both at guideline-recommended doses without pharmacokinetic concern, provided renal function is adequate.